trial_id trialacronym phase recruitmentstatus recruitmentstate approvaldate actualstartdate actualenddate drug_list drug_classes combo_list combo_classes focused_drug_list focused_drug_classes secondaryid studytitle healthcondition postcode ext_weblink ACTRN12613000264785 PCVPON1 Phase 2 / Phase 3 RECRUITING 2013-03-06 none here Immunogenicity and Safety of a 13-valent pneumococcal conjugate vaccine in paediatric oncology patients paediatric malignancy https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000264785 ACTRN12614000552684 The-TIO-Study Phase 1 NOT_YET_RECRUITING 2014-05-22 Irinotecan; Irinotecan + Temozolomide; Temozolomide topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; alkylating_agent Irinotecan + Temozolomide; Temozolomide alkylating_agent; alkylating_agent + topoisomerase_inhibitor Irinotecan; Temozolomide alkylating_agent; topoisomerase_inhibitor Nil A Phase 1 study of Temozolomide, Irinotecan, and O6BG (O6-Benzylguanine) for Children with Recurrent or Resistant Neuroblastoma Recurrent Neuroblastoma; Resistant neuroblastoma https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614000552684 ACTRN12621000246886 AMLM22-D3 Phase 2 NOT_YET_RECRUITING 2021-03-08 SRA515 BRD4_inhibitor SRA515 BRD4_inhibitor SRA515 BRD4_inhibitor NIL AMLM22/D3-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 3 is investigating the safety and efficacy of an Astrazeneca drug labelled AZD5153 as a maintenance therapy option. Acute Myeloid Leukaemia (AML) https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000246886 ACTRN12622000037707 MINI Phase 2 / Phase 3 RECRUITING NSW, QLD, VIC 2022-01-17 2024-06-05 Nil known A prospective, multicentre, randomised, blinded, two-arm parallel trial of Medicinal Cannabis Products for symptom burden in children with advanced cancer Advanced cancer 2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital; 3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health; 3168 - Clayton - Monash Medical Centre; 4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000037707 ACTRN12622000675729 LEVI’S-CATCH Not Applicable RECRUITING NSW 2022-05-10 2023-05-23 Bevacizumab; Bevacizumab + Cyclophosphamide + Fludarabine + GD2-iCAR-PBT; Cyclophosphamide; Fludarabine; GD2-iCAR-PBT; GD2-iCAR-PBT + Radiotherapy; Radiotherapy autologous_CAR-T-cell_therapy,GD2-targeting; alkylating_agent + anti-VEGF_monoclonal_antibody + antimetabolite + autologous_CAR-T-cell_therapy,GD2-targeting; alkylating_agent; radiotherapy; autologous_CAR-T-cell_therapy,GD2-targeting + radiotherapy; antimetabolite; anti-VEGF_monoclonal_antibody Bevacizumab + Cyclophosphamide + Fludarabine + GD2-iCAR-PBT; GD2-iCAR-PBT; GD2-iCAR-PBT + Radiotherapy alkylating_agent + anti-VEGF_monoclonal_antibody + antimetabolite + autologous_CAR-T-cell_therapy,GD2-targeting; autologous_CAR-T-cell_therapy,GD2-targeting; autologous_CAR-T-cell_therapy,GD2-targeting + radiotherapy None A Phase I Study of the Safety of Autologous GD2-Specific Chimeric Antigen Receptor-Expressing T Cells in Children with Diffuse Midline Glioma Central Nervous System Tumour; High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma 2031 - Randwick - Prince of Wales Hospital https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000675729 ACTRN12623000104651 DART Phase 1 RECRUITING NSW, QLD, SA, VIC, WA 2023-01-30 2023-08-29 Deflexifol; Deflexifol + Fluorouracil + Leucovorin; Deflexifol + Radiotherapy; Fluorouracil; Leucovorin; Radiotherapy Fluorouracil + radiotherapy; Fluorouracil + fluoropyrimidine + folinic_acid; Fluorouracil; radiotherapy; folinic_acid Deflexifol; Deflexifol + Fluorouracil + Leucovorin; Deflexifol + Radiotherapy Fluorouracil; Fluorouracil + fluoropyrimidine + folinic_acid; Fluorouracil + radiotherapy Deflexifol Fluorouracil None Phase I Trial of the Safety and Efficacy of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours Central Nervous System Tumour; Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma; Ependymoma 2031 - Randwick - Prince of Wales Hospital; 2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital; 2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital; 3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health; 3168 - Clayton - Monash Medical Centre; 4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre; 5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology; 6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000104651 ACTRN12625001195448 PLATYPS Phase 1 NOT_YET_RECRUITING VIC 2025-10-30 Nil known A Phase I, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of PMCC-COE19 in Patients with CD19-Expressing B-Cell Malignancies CD19 expressing malignancies; CD19 Positive Malignant B-cell Lymphoma; CD19 Positive Malignant B-cell Leukemia 3000 - Melbourne - Peter MacCallum Cancer Centre https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625001195448 NCT02670564 NZ-2015-069--ZH-2014-0535 Phase 4 UNKNOWN 2016-02-02 2013-04-01 Busulfan; Treosulfan alkylating_agent Busulfan; Treosulfan alkylating_agent NZ 2015-069 ZH 2014-0535 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Acute Lymphoblastic Leukemia https://clinicaltrials.gov/ct2/show/NCT02670564 NCT02724163 Myechild01 Phase 3 RECRUITING NSW, NZ, QLD, SA, VIC, WA 2016-03-24 2016-04 2032-12 Busulfan; Busulfan + Cyclophosphamide; Busulfan + Fludarabine; Cyclophosphamide; Cytarabine; Cytarabine + Daunorubicin; Cytarabine + Fludarabine; Cytarabine + Mitoxantrone; Daunorubicin; Fludarabine; Gemtuzumab Ozogamicin; Mitoxantrone anthracycline; alkylating_agent; antineoplastic_antibiotic; anthracycline + antimetabolite; antimetabolite + antineoplastic_antibiotic; antimetabolite; alkylating_agent + antimetabolite; anti-CD33_antibody-drug_conjugate Busulfan + Cyclophosphamide; Busulfan + Fludarabine; Cytarabine; Cytarabine + Daunorubicin; Cytarabine + Fludarabine; Cytarabine + Mitoxantrone; Gemtuzumab Ozogamicin alkylating_agent; alkylating_agent + antimetabolite; anthracycline + antimetabolite; anti-CD33_antibody-drug_conjugate; antimetabolite; antimetabolite + antineoplastic_antibiotic Gemtuzumab Ozogamicin anti-CD33_antibody-drug_conjugate RG_14-088 International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy Acute Myeloid Leukaemia 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 2305 - New Lambton Heights - John Hunter Children's Hospital; 3052 - Parkville - Royal Children's Hospital Melbourne; 3168 - Clayton - Monash Children's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre; 6009 - Perth - Perth Children's Hospital; NZ.1023 - Grafton - Starship Children's Hospital; NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre https://clinicaltrials.gov/ct2/show/NCT02724163 NCT03409081 2215-CL-9200 NO_LONGER_AVAILABLE ACT 2018-01-18 Gilteritinib AXL/FLT3_inhibitor Gilteritinib AXL/FLT3_inhibitor Gilteritinib AXL/FLT3_inhibitor 2215-CL-9200 Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) Acute Myeloid Leukemia (AML); FMS-like Tyrosine Kinase-3 (FLT3) Mutations 2605 - Garran - The Canberra Hospital https://clinicaltrials.gov/ct2/show/NCT03409081 NCT03590171 IntReALL-HR-2010 Phase 2 RECRUITING VIC 2018-07-17 2017-09-01 2027-12-31 Bortezomib proteasome_inhibitor Bortezomib proteasome_inhibitor IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, Münster (BFM) Study Group Acute Lymphoblastic Leukemia (ALL) 3168 - Clayton - Monash Medical Centre https://clinicaltrials.gov/ct2/show/NCT03590171 NCT03601442 CCTL019B2003I AVAILABLE 2018-07-16 Tisagenlecleucel autologous_CAR-T-cell_therapy,CD19-targeting Tisagenlecleucel autologous_CAR-T-cell_therapy,CD19-targeting Tisagenlecleucel autologous_CAR-T-cell_therapy,CD19-targeting CCTL019B2003I Managed Access Programs for CTL019, Tisagenlecleucel Lymphoma; Leukemia; Off-label Indications https://clinicaltrials.gov/ct2/show/NCT03601442 NCT03838042 Final4,-18-10-2023 Phase 1 / Phase 2 RECRUITING NSW, VIC, WA 2019-02-08 2020-05-26 2027-06-30 Entinostat; Entinostat + Nivolumab; Nivolumab HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; HDAC_inhibitor,class_1_selective Entinostat + Nivolumab HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody Entinostat; Nivolumab HDAC_inhibitor,class_1_selective; anti-PD-1_monoclonal_antibody Final4, 18-10-2023 INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt) CNS Tumor; Solid Tumor 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 3052 - Parkville - Royal Children's Hospital Melbourne; 6009 - Perth - Perth Children's Hospital https://clinicaltrials.gov/ct2/show/NCT03838042 NCT03975829 CDRB436G2401 Phase 4 RECRUITING NSW, VIC 2019-06-04 2019-11-04 2026-11-05 Dabrafenib; Dabrafenib + Trametinib; Trametinib BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor; MEK_inhibitor Dabrafenib + Trametinib BRAF_V600_inhibitor + MEK_inhibitor Dabrafenib; Trametinib BRAF_V600_inhibitor; MEK_inhibitor CDRB436G2401 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneuronal Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Liponeurocytoma; Neurofibromatosis Type 1 2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre; 3052 - Parkville - Royal Children's Hospital Melbourne https://clinicaltrials.gov/ct2/show/NCT03975829 NCT04094610 CA127-1029 Phase 1 / Phase 2 RECRUITING NSW, QLD, WA 2019-09-17 2020-03-12 2027-09-30 Repotrectinib TRK_inhibitor,second_generation; ROS1_inhibitor; ALK_inhibitor,third_generation Repotrectinib ALK_inhibitor,third_generation; ROS1_inhibitor; TRK_inhibitor,second_generation Repotrectinib ALK_inhibitor,third_generation; ROS1_inhibitor; TRK_inhibitor,second_generation CA127-1029 A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations Locally Advanced Solid Tumors; Metastatic Solid Tumors; Lymphoma; Primary CNS Tumors 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital https://clinicaltrials.gov/ct2/show/NCT04094610 NCT04293562 AAML1831 Phase 3 RECRUITING NSW, QLD, WA 2020-03-02 2020-07-21 2029-06-30 Asparaginase; Asparaginase + Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Methotrexate + Mitoxantrone; Asparaginase + Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Methotrexate; Asparaginase + Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Methotrexate + Mitoxantrone; Asparaginase + Cytarabine + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate + Mitoxantrone; Asparaginase + Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate; Asparaginase + Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate + Mitoxantrone; Cytarabine; Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Methotrexate; Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Methotrexate; Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate; Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate; Daunorubicin; Dexrazoxane; Etoposide; Gemtuzumab Ozogamicin; Gilteritinib; Liposome-encapsulated Daunorubicin-Cytarabine; Methotrexate; Mitoxantrone anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + asparaginase + iron_chelator + topoisomerase_inhibitor; topoisomerase_inhibitor; AXL/FLT3_inhibitor + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; anti-CD33_antibody-drug_conjugate + antimetabolite + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anti-CD33_antibody-drug_conjugate + antimetabolite + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + antineoplastic_antibiotic + asparaginase + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + iron_chelator + topoisomerase_inhibitor; AXL/FLT3_inhibitor; anti-CD33_antibody-drug_conjugate + antimetabolite + antineoplastic_antibiotic + asparaginase + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + iron_chelator + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + topoisomerase_inhibitor; anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + iron_chelator + topoisomerase_inhibitor; anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + iron_chelator + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anti-CD33_antibody-drug_conjugate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; anti-CD33_antibody-drug_conjugate + antimetabolite + asparaginase + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; anthracycline; anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + topoisomerase_inhibitor; antineoplastic_antibiotic; anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + asparaginase + iron_chelator + topoisomerase_inhibitor; iron_chelator; anti-CD33_antibody-drug_conjugate; liposomal_cytarabine/daunorubicin; antimetabolite; asparaginase; AXL/FLT3_inhibitor + anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + topoisomerase_inhibitor; anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + asparaginase + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor Asparaginase + Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Methotrexate + Mitoxantrone; Asparaginase + Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Methotrexate; Asparaginase + Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Methotrexate + Mitoxantrone; Asparaginase + Cytarabine + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate + Mitoxantrone; Asparaginase + Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate; Asparaginase + Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate + Mitoxantrone; Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Methotrexate; Cytarabine + Daunorubicin + Dexrazoxane + Etoposide + Gemtuzumab Ozogamicin + Methotrexate; Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Gilteritinib + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate; Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Liposome-encapsulated Daunorubicin-Cytarabine + Methotrexate AXL/FLT3_inhibitor + anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + iron_chelator + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + iron_chelator + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anti-CD33_antibody-drug_conjugate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; AXL/FLT3_inhibitor + anti-CD33_antibody-drug_conjugate + antimetabolite + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + topoisomerase_inhibitor; anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + asparaginase + iron_chelator + topoisomerase_inhibitor; anthracycline + anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + iron_chelator + topoisomerase_inhibitor; anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + antineoplastic_antibiotic + asparaginase + iron_chelator + topoisomerase_inhibitor; anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + asparaginase + iron_chelator + topoisomerase_inhibitor; anthracycline + anti-CD33_antibody-drug_conjugate + antimetabolite + iron_chelator + topoisomerase_inhibitor; anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + antineoplastic_antibiotic + asparaginase + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + asparaginase + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; anti-CD33_antibody-drug_conjugate + antifolate + antimetabolite + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; anti-CD33_antibody-drug_conjugate + antimetabolite + antineoplastic_antibiotic + asparaginase + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; anti-CD33_antibody-drug_conjugate + antimetabolite + asparaginase + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor; anti-CD33_antibody-drug_conjugate + antimetabolite + liposomal_cytarabine/daunorubicin + topoisomerase_inhibitor Gemtuzumab Ozogamicin; Gilteritinib; Liposome-encapsulated Daunorubicin-Cytarabine AXL/FLT3_inhibitor; anti-CD33_antibody-drug_conjugate; liposomal_cytarabine/daunorubicin AAML1831 A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations Acute Myeloid Leukemia 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital https://clinicaltrials.gov/ct2/show/NCT04293562 NCT04323046 NCT04323046 Phase 1 RECRUITING NSW, QLD, SA, VIC, WA 2020-03-24 2020-10-02 2029-03-01 Nivolumab anti-PD-1_monoclonal_antibody Nivolumab anti-PD-1_monoclonal_antibody 190815 A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition Followed by Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG) Glioblastoma; Malignant Glioma; Recurrent Glioblastoma; Recurrent Malignant Glioma; Recurrent Grade III Glioma; Grade III Glioma 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 3052 - Parkville - Royal Children's Hospital Melbourne; 4101 - South Brisbane - Queensland Children's Hospital; 5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre; 6009 - Perth - Perth Children's Hospital https://clinicaltrials.gov/ct2/show/NCT04323046 NCT04655404 CONNECT1903 Phase 1 RECRUITING NSW, NZ, QLD, WA 2020-11-30 2021-04-08 2036-12-01 Larotrectinib TRK_inhibitor,first_generation Larotrectinib TRK_inhibitor,first_generation Larotrectinib TRK_inhibitor,first_generation CONNECT1903 A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion High Grade Glioma; Diffuse Intrinsic Pontine Glioma 2031 - Randwick - Sydney Children's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital; NZ.1023 - Grafton - Starship Children's Hospital https://clinicaltrials.gov/ct2/show/NCT04655404 NCT04684368 ACNS2021 Phase 2 RECRUITING NSW, NZ, QLD, VIC, WA 2020-12-22 2021-07-13 2029-12-21 Carboplatin; Carboplatin + Etoposide + Filgrastim + Ifosfamide + Mesna + Pegfilgrastim + Radiotherapy; Carboplatin + Etoposide + Filgrastim + Ifosfamide + Mesna + Pegfilgrastim + Radiotherapy + Thiotepa; Etoposide; Filgrastim; Ifosfamide; Mesna; Pegfilgrastim; Radiotherapy; Thiotepa sodium_mercaptoethanesulfonate; alkylating_agent; topoisomerase_inhibitor; alkylating_agent + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + radiotherapy + sodium_mercaptoethanesulfonate + topoisomerase_inhibitor; platinum-based_antineoplastic_agent; radiotherapy; granulocyte_colony_stimulating_factor Carboplatin + Etoposide + Filgrastim + Ifosfamide + Mesna + Pegfilgrastim + Radiotherapy; Carboplatin + Etoposide + Filgrastim + Ifosfamide + Mesna + Pegfilgrastim + Radiotherapy + Thiotepa alkylating_agent + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + radiotherapy + sodium_mercaptoethanesulfonate + topoisomerase_inhibitor ACNS2021 A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor Central Nervous System Nongerminomatous Germ Cell Tumor; Choriocarcinoma; Embryonal Carcinoma; Immature Teratoma; Malignant Teratoma; Mixed Germ Cell Tumor; Pineal Region Germ Cell Tumor; Pineal Region Immature Teratoma; Pineal Region Yolk Sac Tumor; Suprasellar Germ Cell Tumor 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 3052 - Parkville - Royal Children's Hospital Melbourne; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital; NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre https://clinicaltrials.gov/ct2/show/NCT04684368 NCT04774718 GO42286 Phase 1 / Phase 2 RECRUITING NSW, VIC 2021-02-25 2021-09-14 2032-02-28 Alectinib ALK_inhibitor,second_generation; ALK/RET_inhibitor Alectinib ALK/RET_inhibitor; ALK_inhibitor,second_generation Alectinib ALK/RET_inhibitor; ALK_inhibitor,second_generation GO42286 A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available ALK Fusion-positive Solid or CNS Tumors 2031 - Randwick - Sydney Children's Hospital; 3052 - Parkville - Royal Children's Hospital Melbourne https://clinicaltrials.gov/ct2/show/NCT04774718 NCT04775485 FIREFLY-1 Phase 2 RECRUITING NSW, QLD, VIC, WA 2021-02-25 2021-04-22 2027-05-31 Tovorafenib RAF_inhibitor,type_2 Tovorafenib RAF_inhibitor,type_2 Tovorafenib RAF_inhibitor,type_2 DAY101-001/PNOC026 FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors Low-grade Glioma; Advanced Solid Tumor 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 3052 - Parkville - Royal Children's Hospital Melbourne; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital https://clinicaltrials.gov/ct2/show/NCT04775485 NCT04811560 cAMeLot-1 Phase 1 / Phase 2 RECRUITING QLD, VIC, WA 2021-03-22 2021-05-19 2030-09-22 Bleximenib KMT2A_inhibitor Bleximenib KMT2A_inhibitor Bleximenib KMT2A_inhibitor CR108998 A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1) Acute Leukemia 3168 - Clayton - Monash Medical Centre; 4215 - Southport - Gold Coast University Hospital; 6000 - Perth - Royal Perth Hospital https://clinicaltrials.gov/ct2/show/NCT04811560 NCT04870944 PEPN2111 Phase 1 / Phase 2 RECRUITING NSW 2021-04-28 2022-01-28 2026-12-31 CBL0137 curaxin,FACT_complex-targeting CBL0137 curaxin,FACT_complex-targeting CBL0137 curaxin,FACT_complex-targeting PEPN2111 A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma Diffuse Midline Glioma, H3 K27-Altered; Metastatic Malignant Neoplasm in the Central Nervous System; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Diffuse Midline Glioma, H3 K27-Altered; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Primary Malignant Central Nervous System Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Primary Malignant Central Nervous System Neoplasm 2031 - Randwick - Sydney Children's Hospital https://clinicaltrials.gov/ct2/show/NCT04870944 NCT04884035 CC-220-DLBCL-001 Phase 1 RECRUITING NSW, SA, WA 2021-05-07 2021-09-15 2028-12-01 Cyclophosphamide; Cyclophosphamide + Doxorubicin + Golcadomide + Polatuzumab vedotin + Prednisone + Rituximab; Cyclophosphamide + Doxorubicin + Golcadomide + Prednisone + Rituximab + Vincristine; Cyclophosphamide + Doxorubicin + Iberdomide + Polatuzumab vedotin + Prednisone + Rituximab; Cyclophosphamide + Doxorubicin + Iberdomide + Prednisone + Rituximab + Vincristine; Doxorubicin; Golcadomide; Iberdomide; Polatuzumab vedotin; Prednisone; Rituximab; Vincristine CELMoD_agent; doxorubicin; alkylating_agent; CELMoD_agent + alkylating_agent + anthracycline + anti-CD20_monoclonal_antibody + glucocorticoid + vinca_alkaloid; vinca_alkaloid; anti-CD20_monoclonal_antibody; glucocorticoid; CELMoD_agent + alkylating_agent + anthracycline + anti-CD20_monoclonal_antibody + anti-CD79b_antibody-drug_conjugate + glucocorticoid; anti-CD79b_antibody-drug_conjugate Cyclophosphamide + Doxorubicin + Golcadomide + Polatuzumab vedotin + Prednisone + Rituximab; Cyclophosphamide + Doxorubicin + Golcadomide + Prednisone + Rituximab + Vincristine; Cyclophosphamide + Doxorubicin + Iberdomide + Polatuzumab vedotin + Prednisone + Rituximab; Cyclophosphamide + Doxorubicin + Iberdomide + Prednisone + Rituximab + Vincristine CELMoD_agent + alkylating_agent + anthracycline + anti-CD20_monoclonal_antibody + anti-CD79b_antibody-drug_conjugate + glucocorticoid; CELMoD_agent + alkylating_agent + anthracycline + anti-CD20_monoclonal_antibody + glucocorticoid + vinca_alkaloid; doxorubicin Golcadomide; Iberdomide CELMoD_agent CC-220-DLBCL-001 A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma Lymphoma, B-Cell 2298 - Waratah - Calvary Mater Newcastle Medical Oncology; 5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre; 6000 - Perth - Royal Perth Hospital https://clinicaltrials.gov/ct2/show/NCT04884035 NCT05024929 21-018612 RECRUITING NSW 2021-08-23 2021-07-16 2033-02-01 21-018612 Targeted Therapy to Increase RAI Uptake in Patients With Metastatic Differentiated Thyroid Cancer Papillary Thyroid Cancer; Pediatric Cancer; Differentiated Thyroid Cancer 2145 - Westmead - The Children's Hospital at Westmead https://clinicaltrials.gov/ct2/show/NCT05024929 NCT05099003 NCI-2021-11337 Phase 1 / Phase 2 RECRUITING NSW, NZ, QLD, VIC, WA 2021-10-28 2022-05-31 2027-06-30 Radiotherapy; Radiotherapy + Selinexor; Selinexor radiotherapy; XPO1_inhibitor + radiotherapy; XPO1_inhibitor Radiotherapy + Selinexor XPO1_inhibitor + radiotherapy Radiotherapy; Selinexor XPO1_inhibitor; radiotherapy NCI-2021-11337 A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) Malignant Glioma 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 3052 - Parkville - Royal Children's Hospital Melbourne; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital; NZ.1023 - Grafton - Starship Children's Hospital; NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre https://clinicaltrials.gov/ct2/show/NCT05099003 NCT05183035 ITCC-101-APAL2020D Phase 3 RECRUITING NZ, QLD, VIC, WA 2021-12-21 2022-10-01 2031-04 Azacitidine; Azacitidine + Cytarabine + Fludarabine + Gemtuzumab Ozogamicin + Venetoclax; Cytarabine; Fludarabine; Gemtuzumab Ozogamicin; Venetoclax Bcl2_inhibitor + DNA_methyltransferase_inhibitor + anti-CD33_antibody-drug_conjugate + antimetabolite; antimetabolite; Bcl2_inhibitor + anti-CD33_antibody-drug_conjugate + antimetabolite; Bcl2_inhibitor; anti-CD33_antibody-drug_conjugate Azacitidine + Cytarabine + Fludarabine + Gemtuzumab Ozogamicin + Venetoclax Bcl2_inhibitor + DNA_methyltransferase_inhibitor + anti-CD33_antibody-drug_conjugate + antimetabolite; Bcl2_inhibitor + anti-CD33_antibody-drug_conjugate + antimetabolite Cytarabine; Fludarabine; Gemtuzumab Ozogamicin; Venetoclax Bcl2_inhibitor; anti-CD33_antibody-drug_conjugate; antimetabolite ITCC-101/APAL2020D A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML Acute Myeloid Leukemia 3052 - Parkville - Royal Children's Hospital Melbourne; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital; NZ.1023 - Grafton - Starship Children's Hospital https://clinicaltrials.gov/ct2/show/NCT05183035 NCT05230758 Met-Med-Can Phase 3 RECRUITING NSW, SA, VIC, WA 2022-01-28 2022-07-01 2027-11-30 Metformin; Placebo placebo; biguanide_antihyperglycaemic_agent Metformin; Placebo biguanide_antihyperglycaemic_agent; placebo Metformin; Placebo biguanide_antihyperglycaemic_agent; placebo 1000073107 Phase III Randomized Double-blind Placebo-controlled Trial of Metformin for Cognitive Recovery and White Matter Growth in Paediatric Patients With a Brain Tumour Medulloblastoma, Childhood; Cognitive Impairment 2145 - Westmead - The Children's Hospital at Westmead; 2305 - New Lambton Heights - John Hunter Children's Hospital; 3052 - Parkville - Royal Children's Hospital Melbourne; 3168 - Clayton - Monash Children's Hospital; 5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre; 6009 - Perth - Perth Children's Hospital https://clinicaltrials.gov/ct2/show/NCT05230758 NCT05269771 CINC424B2002I NO_LONGER_AVAILABLE NSW 2022-03-07 Ruxolitinib JAK1/JAK2_inhibitor Ruxolitinib JAK1/JAK2_inhibitor Ruxolitinib JAK1/JAK2_inhibitor CINC424B2002I Treatment Plan for Managed Access Program (MAP) to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera (PV) Polycythemia Vera 2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit https://clinicaltrials.gov/ct2/show/NCT05269771 NCT05304585 ARST2032 Phase 3 RECRUITING NSW, NZ, WA 2022-03-28 2022-08-04 2030-06-30 Cyclophosphamide; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Dactinomycin; Dactinomycin + Vincristine; Radiotherapy; Vincristine antineoplastic_antibiotic + vinca_alkaloid; alkylating_agent; alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; vinca_alkaloid; radiotherapy; antineoplastic_antibiotic Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Dactinomycin + Vincristine alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; antineoplastic_antibiotic + vinca_alkaloid ARST2032 A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma Embryonal Rhabdomyosarcoma; Fusion-Negative Alveolar Rhabdomyosarcoma; Spindle Cell/Sclerosing Rhabdomyosarcoma 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 6009 - Perth - Perth Children's Hospital; NZ.1023 - Grafton - Starship Children's Hospital; NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre https://clinicaltrials.gov/ct2/show/NCT05304585 NCT05327894 Interfant-21 Phase 3 RECRUITING NSW, NZ, QLD, SA, VIC, WA 2022-04-07 2022-12-15 2030-09 Blinatumomab; Blinatumomab + Prednisone; Prednisone bispecific_T-cell_engager,CD19-targeting; bispecific_T-cell_engager,CD19-targeting + glucocorticoid; glucocorticoid Blinatumomab; Blinatumomab + Prednisone bispecific_T-cell_engager,CD19-targeting; bispecific_T-cell_engager,CD19-targeting + glucocorticoid 2021-000213-16 Interfant-21 International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia. Acute Lymphoblastic Leukemia; Mixed Phenotype Acute Leukemia 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 2305 - New Lambton Heights - John Hunter Children's Hospital; 3052 - Parkville - Royal Children's Hospital Melbourne; 3168 - Clayton - Monash Children's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre; 6009 - Perth - Perth Children's Hospital; NZ.8011 - Christchurch - Christchurch Children's Hospital https://clinicaltrials.gov/ct2/show/NCT05327894 NCT05504291 ARET2121 Phase 2 RECRUITING VIC, WA 2022-08-15 2022-11-04 2028-03-31 Carboplatin; Carboplatin + Etoposide + Melphalan + Vincristine; Etoposide; Melphalan; Vincristine platinum-based_antineoplastic_agent; alkylating_agent; alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; vinca_alkaloid; topoisomerase_inhibitor Carboplatin + Etoposide + Melphalan + Vincristine alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid Melphalan alkylating_agent ARET2121 Intravitreal Melphalan for Intraocular Retinoblastoma Bilateral Retinoblastoma; Childhood Intraocular Retinoblastoma; Group D Retinoblastoma; Stage I Retinoblastoma; Unilateral Retinoblastoma 3052 - Parkville - Royal Children's Hospital Melbourne; 6009 - Perth - Perth Children's Hospital https://clinicaltrials.gov/ct2/show/NCT05504291 NCT05533775 iMATRIX-GLO Phase 1 / Phase 2 RECRUITING QLD, WA 2022-09-06 2022-11-16 2032-11-30 Carboplatin; Carboplatin + Etoposide + Glofitamab + Ifosfamide + Obinutuzumab + Rituximab + Tocilizumab; Etoposide; Glofitamab; Glofitamab + Obinutuzumab + Tocilizumab; Ifosfamide; Obinutuzumab; Rituximab; Tocilizumab bispecific_T-cell_engager,CD20-targeting; platinum-based_antineoplastic_agent; alkylating_agent; anti-IL-6_monoclonal_antibody; topoisomerase_inhibitor; anti-CD20_monoclonal_antibody + anti-IL-6_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting; anti-CD20_monoclonal_antibody; alkylating_agent + anti-CD20_monoclonal_antibody + anti-IL-6_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor Carboplatin + Etoposide + Glofitamab + Ifosfamide + Obinutuzumab + Rituximab + Tocilizumab; Glofitamab + Obinutuzumab + Tocilizumab alkylating_agent + anti-CD20_monoclonal_antibody + anti-IL-6_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-CD20_monoclonal_antibody + anti-IL-6_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting Glofitamab bispecific_T-cell_engager,CD20-targeting CO43810 A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma Mature B-Cell Non-Hodgkin Lymphoma 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital https://clinicaltrials.gov/ct2/show/NCT05533775 NCT05839379 CONNECT-TarGeT-SCR RECRUITING NSW, NZ, QLD, VIC, WA 2023-05-01 2024-08-02 2034-08-28 CONNECT TarGeT-SCR Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Glioblastoma; Glioblastoma Multiforme; Diffuse Midline Glioma, H3 K27M-Mutant; Metastatic Brain Tumor; WHO Grade III Glioma; WHO Grade IV Glioma 2031 - Randwick - Sydney Children's Hospital; 3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital; NZ.1023 - Grafton - Starship Children's Hospital https://clinicaltrials.gov/ct2/show/NCT05839379 NCT05843253 CONNECT-TarGeT-A Phase 2 RECRUITING NSW, NZ, QLD, VIC, WA 2023-05-02 2024-08-22 2034-08-28 Everolimus; Everolimus + Ribociclib; Radiotherapy; Ribociclib; Ribociclib + Temozolomide; Temozolomide CDK4/6_inhibitor + mTORC1_inhibitor; CDK4/6_inhibitor; mTORC1_inhibitor; alkylating_agent; CDK4/6_inhibitor + alkylating_agent; radiotherapy Everolimus + Ribociclib; Ribociclib + Temozolomide; Radiotherapy CDK4/6_inhibitor + alkylating_agent; CDK4/6_inhibitor + mTORC1_inhibitor; radiotherapy Everolimus; Radiotherapy; Ribociclib; Temozolomide CDK4/6_inhibitor; alkylating_agent; mTORC1_inhibitor; radiotherapy CONNECT TarGeT-A Phase 2 Study of Ribociclib-Containing Post-Radiotherapy Combinations in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma: Ribociclib and Everolimus for HGG/DIPG Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways AND Ribociclib and Temozolomide for DHG, H3G34-mutant High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Glioblastoma; Glioblastoma Multiforme; Diffuse Midline Glioma, H3 K27M-Mutant; Metastatic Brain Tumor; WHO Grade III Glioma; WHO Grade IV Glioma; Diffuse Hemispheric Glioma, H3 G34-Mutant 2031 - Randwick - Sydney Children's Hospital; 3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital; NZ.1023 - Grafton - Starship Children's Hospital https://clinicaltrials.gov/ct2/show/NCT05843253 NCT05991388 Glo-BNHL Phase 2 / Phase 3 RECRUITING NSW, NZ, QLD, WA 2023-08-07 2024-05-02 2033-05-01 Carboplatin; Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Loncastuximab Tesirine + Rituximab; Dexamethasone; Etoposide; Ifosfamide; Loncastuximab Tesirine; Odronextamab; Rituximab alkylating_agent + anti-CD19_antibody-drug_conjugate + anti-CD20_monoclonal_antibody + glucocorticoid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; bispecific_T-cell_engager,CD20-targeting; platinum-based_antineoplastic_agent; alkylating_agent; topoisomerase_inhibitor; anti-CD20_monoclonal_antibody; glucocorticoid; anti-CD19_antibody-drug_conjugate Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Loncastuximab Tesirine + Rituximab; Odronextamab alkylating_agent + anti-CD19_antibody-drug_conjugate + anti-CD20_monoclonal_antibody + glucocorticoid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; bispecific_T-cell_engager,CD20-targeting RG_21-124 A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma B-cell Non Hodgkin Lymphoma 2145 - Westmead - The Children's Hospital at Westmead; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital; NZ.1023 - Grafton - Starship Children's Hospital https://clinicaltrials.gov/ct2/show/NCT05991388 NCT05999994 CAMPFIRE Phase 2 RECRUITING NSW, VIC 2023-08-14 2020-01-22 2027-05 Abemaciclib; Abemaciclib + Irinotecan + Temozolomide; Cyclophosphamide; Cyclophosphamide + Ramucirumab + Vinorelbine; Cyclophosphamide + Vinorelbine; Docetaxel; Docetaxel + Gemcitabine; Docetaxel + Gemcitabine + Ramucirumab; Gemcitabine; Irinotecan; Irinotecan + Temozolomide; Ramucirumab; Temozolomide; Vinorelbine alkylating_agent; antimetabolite + taxane; anti-VEGFR2_monoclonal_antibody; topoisomerase_inhibitor; CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor; alkylating_agent + vinca_alkaloid; anti-VEGFR2_monoclonal_antibody + antimetabolite + taxane; alkylating_agent + topoisomerase_inhibitor; CDK4/6_inhibitor; vinca_alkaloid; alkylating_agent + anti-VEGFR2_monoclonal_antibody + vinca_alkaloid; taxane; gemcitabine Abemaciclib + Irinotecan + Temozolomide; Cyclophosphamide + Ramucirumab + Vinorelbine; Cyclophosphamide + Vinorelbine; Docetaxel + Gemcitabine; Docetaxel + Gemcitabine + Ramucirumab; Irinotecan + Temozolomide CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor; alkylating_agent + anti-VEGFR2_monoclonal_antibody + vinca_alkaloid; alkylating_agent + topoisomerase_inhibitor; alkylating_agent + vinca_alkaloid; anti-VEGFR2_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; gemcitabine 17304 CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research Neoplasms; Child; Adolescent 2050 - Camperdown - Chris O'Brien Lifehouse; 2145 - Westmead - The Children's Hospital at Westmead; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health https://clinicaltrials.gov/ct2/show/NCT05999994 NCT06124157 NCI-2023-09214 Phase 2 RECRUITING QLD, WA 2023-11-08 2025-05-30 2030-12-01 Asparaginase; Blinatumomab; Blinatumomab + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Doxorubicin + Leucovorin + Methotrexate + Prednisolone + Prednisone + Radiotherapy + Thioguanine + Vincristine; Blinatumomab + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Doxorubicin + Leucovorin + Methotrexate + Prednisolone + Prednisone + Thioguanine + Vincristine; Blinatumomab + Cyclophosphamide + Cytarabine + Daunorubicin + Doxorubicin + Imatinib + Leucovorin + Methotrexate + Prednisolone + Prednisone + Radiotherapy + Thioguanine + Vincristine; Cyclophosphamide; Cytarabine; Dasatinib; Daunorubicin; Doxorubicin; Imatinib; Leucovorin; Methotrexate; Prednisolone; Prednisone; Radiotherapy; Thioguanine; Vincristine BCR-ABL1_inhibitor,first_generation + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; SRC_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; PDGFRA_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; PDGFRA_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; YES1_inhibitor; SRC_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; SRC_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; KIT_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; PDGFRA_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; BCR-ABL1_inhibitor,second_generation + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; YES1_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; BCR-ABL1_inhibitor,first_generation + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; PDGFRA_inhibitor; vinca_alkaloid; glucocorticoid; YES1_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; folinic_acid; KIT_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; anthracycline; doxorubicin; alkylating_agent; BCR-ABL1_inhibitor,second_generation; SRC_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; KIT_inhibitor; bispecific_T-cell_engager,CD19-targeting; PDGFRA_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; YES1_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; BCR-ABL1_inhibitor,second_generation + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; YES1_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; radiotherapy; BCR-ABL1_inhibitor,second_generation + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; BCR-ABL1_inhibitor,first_generation; KIT_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; antimetabolite; asparaginase; KIT_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; BCR-ABL1_inhibitor,second_generation + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; SRC_inhibitor Blinatumomab + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Doxorubicin + Leucovorin + Methotrexate + Prednisolone + Prednisone + Radiotherapy + Thioguanine + Vincristine; Blinatumomab + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Doxorubicin + Leucovorin + Methotrexate + Prednisolone + Prednisone + Thioguanine + Vincristine; Blinatumomab + Cyclophosphamide + Cytarabine + Daunorubicin + Doxorubicin + Imatinib + Leucovorin + Methotrexate + Prednisolone + Prednisone + Radiotherapy + Thioguanine + Vincristine; Asparaginase BCR-ABL1_inhibitor,first_generation + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; BCR-ABL1_inhibitor,first_generation + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; BCR-ABL1_inhibitor,second_generation + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; BCR-ABL1_inhibitor,second_generation + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; BCR-ABL1_inhibitor,second_generation + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; BCR-ABL1_inhibitor,second_generation + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; KIT_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; KIT_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; KIT_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; KIT_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; PDGFRA_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; PDGFRA_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; PDGFRA_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; PDGFRA_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; SRC_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; SRC_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; SRC_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; SRC_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; YES1_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; YES1_inhibitor + alkylating_agent + anthracycline + antifolate + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; YES1_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + radiotherapy + vinca_alkaloid; YES1_inhibitor + alkylating_agent + anthracycline + antimetabolite + bispecific_T-cell_engager,CD19-targeting + folinic_acid + glucocorticoid + vinca_alkaloid; asparaginase; doxorubicin Blinatumomab bispecific_T-cell_engager,CD19-targeting NCI-2023-09214 An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital https://clinicaltrials.gov/ct2/show/NCT06124157 NCT06137118 SYRUS Phase 1 / Phase 2 RECRUITING VIC 2023-11-13 2023-12-29 2027-06-29 Surovatamig bispecific_T-cell_engager,CD19-targeting Surovatamig bispecific_T-cell_engager,CD19-targeting Surovatamig bispecific_T-cell_engager,CD19-targeting D7405C00001 A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia B-cell Acute Lymphoblastic Leukemia (B-ALL) 3000 - Melbourne - Peter MacCallum Cancer Centre https://clinicaltrials.gov/ct2/show/NCT06137118 NCT06137144 PRIMAVERA Phase 1 / Phase 2 RECRUITING NSW, QLD, SA, VIC, WA 2023-11-13 2024-01-23 2029-04-30 AZD3470; AZD3470 + Pembrolizumab; Pembrolizumab PRMT5_inhibitor,MTA-co-operative; PRMT5_inhibitor,MTA-co-operative + anti-PD-1_monoclonal_antibody; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; PRMT5_inhibitor AZD3470; AZD3470 + Pembrolizumab PRMT5_inhibitor; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody; PRMT5_inhibitor,MTA-co-operative; PRMT5_inhibitor,MTA-co-operative + anti-PD-1_monoclonal_antibody AZD3470 PRMT5_inhibitor; PRMT5_inhibitor,MTA-co-operative D9971C00001 A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies Lymphoma; Non-Hodgkin Lymphoma; Hodgkin Lymphoma; Peripheral T-cell Lymphoma (PTCL); PTCL-NOS; ALCL; AITL 2298 - Waratah - Calvary Mater Newcastle Medical Oncology; 3065 - Fitzroy - St Vincent's Hospital Melbourne; 4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre; 4575 - Birtinya - Sunshine Coast University Hospital; 5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre; 6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre https://clinicaltrials.gov/ct2/show/NCT06137144 NCT06161974 TarGeT-D Phase 2 RECRUITING NSW, QLD, WA 2023-11-30 2025-03 2035-06 Olutasidenib; Olutasidenib + Temozolomide; Temozolomide IDH1_R132_inhibitor + alkylating_agent; alkylating_agent; IDH1_R132_inhibitor Olutasidenib + Temozolomide IDH1_R132_inhibitor + alkylating_agent Olutasidenib; Temozolomide IDH1_R132_inhibitor; alkylating_agent TarGeT-D Phase 2 Study of Olutasidenib with Temozolomide As Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations High Grade Glioma; Astrocytoma; Astrocytoma, Grade III; Astrocytoma, Grade IV; Diffuse Intrinsic Pontine Glioma; WHO Grade III Glioma; WHO Grade IV Glioma; Metastatic Brain Tumor; Diffuse Midline Glioma, H3 K27M-Mutant; Thalamus Tumor; Spinal Tumor; IDH1 Mutation; IDH1 R132; IDH1 R132C; IDH1 R132H; IDH1 R132S; IDH1 R132G; IDH1 R132L; Oligodendroglioma 2031 - Randwick - Sydney Children's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital https://clinicaltrials.gov/ct2/show/NCT06161974 NCT06208657 OPTIMISE Phase 1 / Phase 2 RECRUITING NSW, QLD, SA, TAS, VIC, WA 2024-01-05 2024-07-10 2035-12 Irinotecan; Irinotecan + Paxalisib + Temozolomide; Nivolumab; Nivolumab + Relatlimab; Paxalisib; Relatlimab; Temozolomide alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; alkylating_agent; topoisomerase_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; dual_PI3K/mTOR_inhibitor Irinotecan + Paxalisib + Temozolomide; Nivolumab + Relatlimab alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody OPTIMISE Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Childhood Cancer; Childhood Solid Tumor; Childhood Brain Tumor; Recurrent Cancer; Refractory Cancer 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 2305 - New Lambton Heights - John Hunter Children's Hospital; 3052 - Parkville - Royal Children's Hospital Melbourne; 3168 - Clayton - Monash Children's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre; 6009 - Perth - Perth Children's Hospital; 7000 - Hobart - Royal Hobart Hospital https://clinicaltrials.gov/ct2/show/NCT06208657 NCT06302426 INI-4001-101 Phase 1 RECRUITING NSW, SA, VIC 2024-03-04 2024-07-01 2027-03-30 Atezolizumab; Atezolizumab + Avelumab + Cemiplimab + Durvalumab + INI-4001 + Nivolumab + Pembrolizumab; Avelumab; Cemiplimab; Durvalumab; INI-4001; Nivolumab; Pembrolizumab anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; TLR7/TLR8_agonist; TLR7/TLR8_agonist + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody Atezolizumab + Avelumab + Cemiplimab + Durvalumab + INI-4001 + Nivolumab + Pembrolizumab TLR7/TLR8_agonist + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody INI-4001 TLR7/TLR8_agonist INI-4001-101 An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours Advanced Solid Tumor 2640 - Albury - Border Medical Oncology Research Unit; 3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre; 5042 - Bedford Park - Southern Oncology Clinical Research Unit https://clinicaltrials.gov/ct2/show/NCT06302426 NCT06304818 SCTB14-X101 Phase 1 / Phase 2 NOT_YET_RECRUITING 2024-03-05 2024-04-30 2028-12-30 SCTB14 bispecific_PD-1/VEGF_antibody SCTB14 bispecific_PD-1/VEGF_antibody SCTB14 bispecific_PD-1/VEGF_antibody SCTB14-X101 A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB14 in Patients With Advanced Malignant Solid Tumours Advanced Malignant Solid Tumours https://clinicaltrials.gov/ct2/show/NCT06304818 NCT06333899 CONNECT-TarGeT-L Phase 1 RECRUITING NSW, NZ, QLD, WA 2024-03-20 2025-08-03 2035-06-01 Carboplatin; Carboplatin + Cyclophosphamide + Lorlatinib + Methotrexate + Vincristine; Cisplatin; Cisplatin + Cyclophosphamide + Lorlatinib + Vincristine; Cyclophosphamide; Lorlatinib; Lorlatinib + Radiotherapy; Methotrexate; Radiotherapy; Tegafur-gimeracil-oteracil potassium; Vincristine ROS1_inhibitor + alkylating_agent + antifolate + platinum-based_antineoplastic_agent + vinca_alkaloid; alkylating_agent; ROS1_inhibitor + alkylating_agent + platinum-based_antineoplastic_agent + vinca_alkaloid; ALK_inhibitor,third_generation + alkylating_agent + platinum-based_antineoplastic_agent + vinca_alkaloid; DPD_inhibitor; ROS1_inhibitor + alkylating_agent + antimetabolite + platinum-based_antineoplastic_agent + vinca_alkaloid; ROS1_inhibitor; ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + alkylating_agent + antifolate + platinum-based_antineoplastic_agent + vinca_alkaloid; ALK_inhibitor,third_generation + radiotherapy; platinum-based_antineoplastic_agent; vinca_alkaloid; radiotherapy; ROS1_inhibitor + radiotherapy; antimetabolite; orotate_phosphoribosyltransferase_inhibitor; ALK_inhibitor,third_generation + alkylating_agent + antimetabolite + platinum-based_antineoplastic_agent + vinca_alkaloid Carboplatin + Cyclophosphamide + Lorlatinib + Methotrexate + Vincristine; Cisplatin + Cyclophosphamide + Lorlatinib + Vincristine; Lorlatinib; Lorlatinib + Radiotherapy; Tegafur-gimeracil-oteracil potassium ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + alkylating_agent + antifolate + platinum-based_antineoplastic_agent + vinca_alkaloid; ALK_inhibitor,third_generation + alkylating_agent + antimetabolite + platinum-based_antineoplastic_agent + vinca_alkaloid; ALK_inhibitor,third_generation + alkylating_agent + platinum-based_antineoplastic_agent + vinca_alkaloid; ALK_inhibitor,third_generation + radiotherapy; ROS1_inhibitor; ROS1_inhibitor + alkylating_agent + antifolate + platinum-based_antineoplastic_agent + vinca_alkaloid; ROS1_inhibitor + alkylating_agent + antimetabolite + platinum-based_antineoplastic_agent + vinca_alkaloid; ROS1_inhibitor + alkylating_agent + platinum-based_antineoplastic_agent + vinca_alkaloid; ROS1_inhibitor + radiotherapy; DPD_inhibitor; orotate_phosphoribosyltransferase_inhibitor Lorlatinib ALK_inhibitor,third_generation; ROS1_inhibitor CONNECT TarGeT-L A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Infant Type Hemispheric Glioma; Glioblastoma; Glioblastoma Multiforme; WHO Grade III Glioma; WHO Grade IV Glioma; Diffuse Midline Glioma, H3K27-altered 2031 - Randwick - Sydney Children's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital; NZ.1023 - Grafton - Starship Children's Hospital https://clinicaltrials.gov/ct2/show/NCT06333899 NCT06381570 VICTORY Phase 0 RECRUITING 2024-04-24 2024-03-21 Tovorafenib; Vinblastine vinca_alkaloid; RAF_inhibitor,type_2 Tovorafenib; Vinblastine RAF_inhibitor,type_2; vinca_alkaloid Tovorafenib; Vinblastine RAF_inhibitor,type_2; vinca_alkaloid VICTORY/OZM-138 VICTORY: A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine With Oral Type II RAF Inhibitor Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas Low-grade Glioma https://clinicaltrials.gov/ct2/show/NCT06381570 NCT06395103 9999-01A Phase 1 / Phase 2 RECRUITING NSW, QLD, VIC 2024-04-29 2024-08-16 2029-03-31 Zilovertamab vedotin anti-ROR1_antibody-drug_conjugate Zilovertamab vedotin anti-ROR1_antibody-drug_conjugate Zilovertamab vedotin anti-ROR1_antibody-drug_conjugate 9999-01A LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma; Burkitt Lymphoma; Neuroblastoma; Ewing Sarcoma 2031 - Randwick - Sydney Children's Hospital; 3052 - Parkville - Royal Children's Hospital Melbourne; 4101 - South Brisbane - Queensland Children's Hospital https://clinicaltrials.gov/ct2/show/NCT06395103 NCT06401330 AREN2231 Phase 3 RECRUITING QLD 2024-05-02 2025-04-15 2031-02-13 Carboplatin; Carboplatin + Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Irinotecan + Vincristine; Carboplatin + Cyclophosphamide + Doxorubicin + Etoposide + Irinotecan + Vincristine; Cyclophosphamide; Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide; Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Irinotecan + Vincristine; Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Vincristine; Cyclophosphamide + Doxorubicin + Etoposide + Irinotecan + Vincristine; Cyclophosphamide + Doxorubicin + Etoposide + Vincristine; Dactinomycin; Dactinomycin + Doxorubicin + Etoposide + Irinotecan + Vincristine; Dactinomycin + Doxorubicin + Vincristine; Dactinomycin + Irinotecan + Vincristine; Dactinomycin + Vincristine; Doxorubicin; Etoposide; Irinotecan; Vincristine alkylating_agent + anthracycline + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; doxorubicin; alkylating_agent + anthracycline + antineoplastic_antibiotic + topoisomerase_inhibitor; alkylating_agent; antineoplastic_antibiotic; topoisomerase_inhibitor; alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid; antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + anthracycline + antineoplastic_antibiotic + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; antineoplastic_antibiotic + vinca_alkaloid; anthracycline + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; platinum-based_antineoplastic_agent; anthracycline + antineoplastic_antibiotic + vinca_alkaloid; vinca_alkaloid; alkylating_agent + anthracycline + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid Carboplatin + Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Irinotecan + Vincristine; Carboplatin + Cyclophosphamide + Doxorubicin + Etoposide + Irinotecan + Vincristine; Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide; Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Irinotecan + Vincristine; Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Vincristine; Cyclophosphamide + Doxorubicin + Etoposide + Irinotecan + Vincristine; Cyclophosphamide + Doxorubicin + Etoposide + Vincristine; Dactinomycin + Doxorubicin + Etoposide + Irinotecan + Vincristine; Dactinomycin + Doxorubicin + Vincristine; Dactinomycin + Irinotecan + Vincristine; Dactinomycin + Vincristine alkylating_agent + anthracycline + antineoplastic_antibiotic + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + anthracycline + antineoplastic_antibiotic + topoisomerase_inhibitor; alkylating_agent + anthracycline + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + anthracycline + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid; anthracycline + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; anthracycline + antineoplastic_antibiotic + vinca_alkaloid; antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; antineoplastic_antibiotic + vinca_alkaloid; doxorubicin AREN2231 Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) Stage I Mixed Cell Type Kidney Wilms Tumor; Stage II Mixed Cell Type Kidney Wilms Tumor; Stage III Mixed Cell Type Kidney Wilms Tumor; Stage IV Mixed Cell Type Kidney Wilms Tumor 4101 - South Brisbane - Queensland Children's Hospital https://clinicaltrials.gov/ct2/show/NCT06401330 NCT06414148 EpLCART Phase 2 RECRUITING NSW, QLD, VIC, WA 2024-05-09 2024-05-14 2028-05 Epcoritamab; Epcoritamab + Lenalidomide + Rituximab; Lenalidomide; Rituximab anti-CD20_monoclonal_antibody; bispecific_T-cell_engager,CD20-targeting; immunomodulatory_imide_drug; anti-CD20_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting + immunomodulatory_imide_drug Epcoritamab; Epcoritamab + Lenalidomide + Rituximab anti-CD20_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting + immunomodulatory_imide_drug; bispecific_T-cell_engager,CD20-targeting Epcoritamab; Lenalidomide; Rituximab anti-CD20_monoclonal_antibody; bispecific_T-cell_engager,CD20-targeting; immunomodulatory_imide_drug 22/012 A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART) Relapsed/Refractory Large B-cell Lymphoma 2050 - Camperdown - Chris O'Brien Lifehouse; 2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne, Southbank - Alfred Health; 4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre; 6150 - Murdoch - Fiona Stanley Hospital https://clinicaltrials.gov/ct2/show/NCT06414148 NCT06514794 WUC007-03 Phase 2 RECRUITING VIC 2024-07-17 2025-01-31 2028-12-30 WU-CART-007 allogeneic_CAR-T-cell_therapy,CD7-targeting WU-CART-007 allogeneic_CAR-T-cell_therapy,CD7-targeting WU-CART-007 allogeneic_CAR-T-cell_therapy,CD7-targeting WUC007-03 A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex) T-cell Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma 3000 - Melbourne - Peter MacCallum Cancer Centre; 3052 - Parkville - Royal Children's Hospital Melbourne https://clinicaltrials.gov/ct2/show/NCT06514794 NCT06838676 CONNECT2110 Phase 2 RECRUITING NSW, NZ, QLD, VIC, WA 2025-02-19 2025-07-10 2035-07 DMAMCL NFKB_inhibitor DMAMCL NFKB_inhibitor DMAMCL NFKB_inhibitor CONNECT2110 A Phase II Trial of ACT001 in Children and Adolescents With Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas Diffuse Intrinsic Pontine Gliomas (DIPG); Progressive DIPG; Refractory DIPG; Recurrent DIPG; H3K27-altered High Grade Glioma 2031 - Randwick - Sydney Children's Hospital; 3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital; NZ.1023 - Grafton - Starship Children's Hospital https://clinicaltrials.gov/ct2/show/NCT06838676 NCT06876649 NCT06876649 Phase 4 RECRUITING SA, VIC, WA 2025-03-13 2025-05-20 2032-12 Pirtobrutinib BTK_inhibitor Pirtobrutinib BTK_inhibitor Pirtobrutinib BTK_inhibitor 27202 A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma 3000 - Melbourne - Peter MacCallum Cancer Centre; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - Linear Clinical Research https://clinicaltrials.gov/ct2/show/NCT06876649 NCT06941272 9999-01C Phase 1 / Phase 2 RECRUITING NSW, QLD 2025-04-15 2025-05-26 2030-12-30 Patritumab Deruxtecan anti-ERBB3_antibody-drug_conjugate Patritumab Deruxtecan anti-ERBB3_antibody-drug_conjugate Patritumab Deruxtecan anti-ERBB3_antibody-drug_conjugate 9999-01C LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors Malignant Neoplasm 2031 - Randwick - Sydney Children's Hospital; 4101 - South Brisbane - Queensland Children's Hospital https://clinicaltrials.gov/ct2/show/NCT06941272 NCT07060807 1022-016 Phase 3 RECRUITING NSW, VIC 2025-07-02 2025-07-21 2033-07-14 Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin + Trastuzumab Deruxtecan; Nab-paclitaxel; Paclitaxel; Patritumab Deruxtecan; Pegylated liposomal doxorubicin; Trastuzumab Deruxtecan anti-ERBB3_antibody-drug_conjugate; anthracycline + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine + taxane; anti-ERBB2_antibody-drug_conjugate; anthracycline; fluoropyrimidine; taxane Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin + Trastuzumab Deruxtecan; Patritumab Deruxtecan anthracycline + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine + taxane; anti-ERBB3_antibody-drug_conjugate Patritumab Deruxtecan anti-ERBB3_antibody-drug_conjugate 1022-016 An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04) Breast Neoplasms 2050 - Camperdown - Chris O'Brien Lifehouse; 2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre; 3004 - Melbourne, Southbank - Alfred Health; 3168 - Clayton - Monash Medical Centre https://clinicaltrials.gov/ct2/show/NCT07060807 NCT07109219 ALLight Phase 1 / Phase 2 RECRUITING VIC 2025-07-31 2025-11-12 2028-07-03 AZD4512 anti-CD22_antibody-drug_conjugate AZD4512 anti-CD22_antibody-drug_conjugate AZD4512 anti-CD22_antibody-drug_conjugate D9891C00001 A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia B-cell Acute Lymphoblastic Leukemia (B-ALL) 3000 - Melbourne - Peter MacCallum Cancer Centre https://clinicaltrials.gov/ct2/show/NCT07109219 NCT07190300 TulmiSTAR-02 Phase 1 / Phase 2 RECRUITING NSW 2025-09-16 2026-01-13 2032-08-02 Abiraterone; Abiraterone + Tulmimetostat; Darolutamide; Darolutamide + Tulmimetostat; Tulmimetostat CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation; EZH1/2_inhibitor; EZH1/2_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + EZH1/2_inhibitor Abiraterone + Tulmimetostat; Darolutamide; Darolutamide + Tulmimetostat CYP17A1_inhibitor + EZH1/2_inhibitor; EZH1/2_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation Abiraterone; Darolutamide; Tulmimetostat CYP17A1_inhibitor; EZH1/2_inhibitor; antiandrogen,nonsteroidal,second_generation CDZR123C12101 TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 2050 - Camperdown - Chris O'Brien Lifehouse; 2500 - Wollongong - Wollongong Hospital https://clinicaltrials.gov/ct2/show/NCT07190300 NCT07306832 M25-692 Phase 1 RECRUITING WA 2025-12-15 2026-05-20 2030-03 M25-692 A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia 6009 - Perth - Perth Children's Hospital https://clinicaltrials.gov/ct2/show/NCT07306832 NCT07334301 BEACON2 Phase 1 / Phase 2 RECRUITING NSW, NZ 2026-01-05 2024-11-11 2030-12-31 Bevacizumab; Bevacizumab + Dinutuximab + Irinotecan + Temozolomide + Topotecan; Bevacizumab + Irinotecan + Temozolomide + Topotecan; Dinutuximab; Dinutuximab + Irinotecan + Temozolomide + Topotecan; Irinotecan; Temozolomide; Topotecan alkylating_agent + anti-GD2_monoclonal_antibody + topoisomerase_inhibitor; alkylating_agent; topoisomerase_inhibitor; anti-GD2_monoclonal_antibody; alkylating_agent + anti-VEGF_monoclonal_antibody + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody; alkylating_agent + anti-GD2_monoclonal_antibody + anti-VEGF_monoclonal_antibody + topoisomerase_inhibitor Bevacizumab + Dinutuximab + Irinotecan + Temozolomide + Topotecan; Bevacizumab + Irinotecan + Temozolomide + Topotecan; Dinutuximab + Irinotecan + Temozolomide + Topotecan alkylating_agent + anti-GD2_monoclonal_antibody + anti-VEGF_monoclonal_antibody + topoisomerase_inhibitor; alkylating_agent + anti-GD2_monoclonal_antibody + topoisomerase_inhibitor; alkylating_agent + anti-VEGF_monoclonal_antibody + topoisomerase_inhibitor RG_22-136 A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Relapsed Neuroblastoma 2031 - Randwick - Sydney Children's Hospital; NZ.1023 - Grafton - Starship Children's Hospital https://clinicaltrials.gov/ct2/show/NCT07334301 NCT07354074 CABL001I12202 Phase 2 RECRUITING QLD 2026-01-16 2026-04-28 2033-02-23 Asciminib BCR-ABL1_inhibitor Asciminib BCR-ABL1_inhibitor Asciminib BCR-ABL1_inhibitor CABL001I12202 A Phase II, Multicenter, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Participants Newly Diagnosed or Previously Treated With Philadelphia Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) With or Without Known T315I Mutation Chronic Myelogenous Leukemia; Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive 4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre https://clinicaltrials.gov/ct2/show/NCT07354074